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Abstract: Cutaneous T cell lymphomas (CTCL) clinically and biologically represent a 
heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome 
being the most common subtypes. Over the last decade, new immunological and molecular 
pathways have been identified that not only influence CTCL phenotype and growth, but also 
provide targets for therapies and prognostication. This review will focus on recent advances in 
the development of therapeutic agents, including bortezomib, the histone deacetylase inhibitors 
(vorinostat and romidepsin), and pralatrexate in CTCL.
Keywords: novel targets, histone deacetylase inhibitors, pralatrexate, bortezomib, cutaneous 
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Introduction
Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of non-Hodgkin 
lymphomas characterized by an initial infiltration of the skin with clonally-derived 
malignant T lymphocytes of the CD4+ CD45RO+ phenotype that generally lack   normal 
T cell markers, such as CD7 and CD26.1 The diversity of clinical and   pathologic mani-
festations among subsets of CTCL has led to much controversy over its diagnosis and 
classification and to the establishment of consensus guidelines by a joint effort of the 
World Health Organization and European Organization for Research and T  reatment 
of Cancer (WHO-EORTC) in 2005.2
The two most common types of CTCL are mycosis fungoides (50%–72%), which 
is generally indolent in behavior, and Sézary syndrome (1%–3%), an aggressive 
l  eukemic form of the disease (Table 1).2–5 Other types include primary cutaneous 
CD30+   lymphoproliferative disorders, subcutaneous panniculitis-like T cell lymphoma, 
and the group of primary cutaneous peripheral T cell lymphomas that includes the 
provisional entities of cutaneous aggressive epidermotropic CD8+ T cell lymphoma, 
cutaneous γ/δ T cell lymphoma, and cutaneous CD4+ small/medium-sized pleomorphic 
T cell lymphoma.4,6
Mycosis fungoides and Sézary syndrome together comprise 54% of all CTCL.2 The 
annual incidence of CTCL in the United States has increased from 2.8 per   million (1973–
1977) to 9.6 per million (1998–2002) according to data from Criscione and   Weinstock.5 
Median age at presentation is between 50 and 70 years,5,7,8 although p  ediatric and young 
adult cases do occur.9,10 Mycosis fungoides classically presents with an indolent course and 
slow progression over years or sometimes decades. The disease may evolve from patches 
to infiltrated plaques and eventually to tumors (F  igure 1A and B). However, about 30% of 
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Table 1 European Organization for Research and Treatment of 
Cancer consensus classification for primary cutaneous lymphomas 
with relative frequency and 5-year survival
WHO-EORTC Frequency  
(%)
5-year survival  
(%)
Cutaneous T cell and natural killer cell lymphoma
indolent
Mycosis fungoides 
Follicular mycosis fungoides 
• Pagetoid reticulosis 
• Granulomatous slack skin
44 
4 
,1 
,1
88 
80 
100 
100
CD30+ lymphoproliferative  
disorders 
•   Anaplastic large cell  
lymphoma
• Lymphomatoid papulosis
 
 
8 
 
12
 
 
95 
 
100
Subcutaneous panniculitis- 
like T cell lymphoma
1 82
CD4+ small/medium  
pleomorphic T cell lymphoma
2 72
Aggressive
Sézary syndrome 3 24
Cutaneous peripheral T cell 
lymphoma, unspecified 
•   Cutaneous aggressive  
CD8+ T cell lymphoma
•   Cutaneous γ/δ T cell  
lymphoma
2 
 
 
,1 
,1
16 
 
18 
 
–
Cutaneous natural killer/ 
T cell lymphoma, nasal-type
,1 –
Cutaneous B cell lymphoma
indolent
Follicle center cell lymphoma 11 95
Marginal zone lymphoma 7 99
intermediate clinical behavior
Large B cell lymphoma  
of the leg
4 55
Cutaneous diffuse large  
B cell lymphoma, other
,1 50
intravascular large  
B cell lymphoma
,1 65
Copyright  ©  2005,  American  Society  of  Hematology.  Adapted  with  permission 
from Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous 
lymphomas. Blood. 2005;105(10):3768–3785.
Abbreviations:  wHO,  world  Health  Organization;  EORTC,  European 
Organization for Research and Treatment of Cancer.
patients present with skin tumors (T3) or erythroderma (T4) at 
initial   presentation.8 Sézary syndrome is a much more aggres-
sive disease. Patients with Sézary syndrome present with eryth-
roderma, circulating malignant T cells (Sézary cells), and severe 
disabling pruritus with or without associated lymphadenopathy 
 ( Figure 2). The TNMB (tumor, node, metastasis, blood) clas-
sification for clinical staging is used according to the Mycosis 
Fungoides Cooperative Group staging system11 established 
in 1979 by Bunn and Lamberg, which was revised by the 
  International Society for Cutaneous Lymphomas/European 
Organization for Research and Treatment of Cancer (EORTC) 
Figure 1 Patients with mycosis fungoides presenting with limited (A) patches/
plaques typically involving the buttocks, and with disseminated (B) patches/plaques 
and tumors.
staging proposal in 2007.12 Advanced clinical stages range from 
IIB (skin tumors) to IVB (visceral disease).
While the overall survival rate of patients with   mycosis 
fungoides is 68% at 5 years and 17% at 30 years, the 
s  pecific survival of patients ranges widely, depending on 
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T   classification and stage at initial presentation.8 The largest 
study, consisting of 525 patients, showed an overall survival 
of 97% in patients with T1 (less than 10% body surface 
involvement) at 5 years, compared with 40% and 41% in 
T3 and T4 disease, respectively.8 Other studies have shown 
that elevated lactate dehydrogenase, large-cell transforma-
tion, and folliculotropic mycosis fungoides are associated 
with a worse prognosis.13,14 Patients with Sézary syndrome 
have an estimated 5-year survival of 24%.4,8 Recent analyses 
of outcomes in patients with mycosis fungoides or Sézary 
syndrome using the International Society for Cutaneous 
Lymphoma/EORTC revised staging proposal established 
that the presence of a T cell clone in blood (identical to the 
cutaneous T cell clone) in the absence of morphologic evi-
dence of blood involvement (B0b) was also associated with 
a significantly worse overall survival and disease-specific 
survival compared with those patients with no peripheral 
blood T cell clone (B0a).12,13
Research on new therapies for CTCL is largely centered 
on defining novel targets for therapy. The International   Society 
for Cutaneous Lymphomas, the United States Cutaneous 
Lymphoma Consortium, and the Cutaneous Lymphoma Task 
Force of the EORTC have developed consensus guidelines 
to facilitate collaboration in clinical trials.15 These proposed 
guidelines consist of: recommendations for standardizing 
general protocol design; a scoring system for assessing tumor 
burden in skin, lymph nodes, blood, and viscera; definition of 
response in skin, nodes, blood, and viscera; a composite global 
response score; and a definition of end points. Although these 
guidelines were generated by consensus panels, they have not 
been prospectively or retrospectively validated by analysis 
of large patient cohorts. This review focuses on current and 
new discoveries that have provided targets for therapy in 
patients with mycosis fungoides or Sézary syndrome. We will 
briefly give an overview of recent molecular discoveries and 
dysregulated signaling pathways, followed by a presentation 
of current and novel topical, biological, and chemotherapy 
treatments for CTCL patients.
Immunologic and molecular findings 
in mycosis fungoides and Sézary 
syndrome
immunologic mechanisms of pathogenesis
Most malignant T cells in CTCL are clonally derived from 
CD4+ T helper memory cells.16 In the early stages of myco-
sis fungoides, the T cell infiltrate consists of both malignant 
CD4+ and reactive CD8+ T cells, with a dominance of Th1 
cytokines, such as interferon-gamma (IFN)-γ, interleukin 
(IL)-12, and IL-2.17 In the later stages, there is a gradual 
increase in malignant CD4+ cells, a decrease in nonma-
lignant CD8+ cells, and a shift to Th2 cytokine dominance 
(IL-4, IL-5, IL-10, and IL-13).18 These changes correlate 
with disease progression, host immunosuppression, and 
susceptibility to infection.19 Biologic immune modifiers, such 
as IFN-α, IFN-γ, and IL-12, are therapeutically effective 
in CTCL by stimulating Th1 cytokines and boosting host 
immune responses. The recently discovered Th17 lineage 
of CD4+ T cells functions in host protection against extra-
cellular bacteria and fungi.20 Th17-derived cytokines (IL-17, 
IL-21, and IL-22) have been implicated in autoimmunity.21 
Recently, the Th1/Th2 paradigm of CTCL has been revisited, 
including a role for a IL-17-producing T cell (Th17) popula-
tion in cutaneous lesions of patients with mycosis fungoides 
or Sézary syndrome.22 Interestingly, IL-17 was not measur-
able in serum samples of patients with mycosis fungoides 
or Sézary syndrome, suggesting that this cytokine may only 
play a role in cutaneous lesions. In another study, IL-17 
protein was found to be mediated by IL-2/IL-15 through the 
Jak3/STAT3 pathway.23 Other immune regulatory molecules 
found to be overexpressed in CTCL include IL-15, IL-16, 
and IL-21, and programmed death-1 (PD-1).24–27
Controversial results have been found for PD-1 
  expression. Increased PD-1 expression has been shown on 
circulating CD4+ cells in patients with Sézary syndrome 
Figure  2  Patient  with  Sézary  syndrome  presenting  clinically  with  generalized 
erythroderma and thickening (lichenification) of the skin.
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when compared with patients with mycosis fungoides, 
which could imply a role for an increase in PD-1 expres-
sion in the progression of tumors.26 However, recent data 
showed increased PD-1 in pseudolymphoma and cutaneous 
CD4+ small/medium-sized pleomorphic T cell lymphoma.28 
Further research is needed in this area to determine whether 
the increase in PD-1 expression protects tumor cells from 
elimination, or if the increased PD-1 expression is a response 
of immunocompetent cells that are simply chronically stimu-
lated by tumor antigens.
Chemokines and chemokine receptors in CTCL have been 
reviewed by others.29,30 They mediate not only trafficking of 
malignant T cells into the skin, but also their survival, pos-
sibly due to activation of prosurvival pathways. Chemokine 
receptor 4 (CCR4) is not only necessary for skin-homing of 
normal CD4+ T lymphocytes, but also for malignant CTCL 
cells.31,32 Both CCR4 and CCR10 have been shown to be 
highly expressed in CTCL skin lesions33 and in the peripheral 
blood cells of patients with mycosis fungoides or Sézary 
syndrome.34,35 While CCL17, a CCR4 ligand expressed on 
epidermal keratinocytes, endothelial cells, and dendritic cells, 
facilitates extravasation and migration of CTCL cells into 
the skin and epidermis, CCL27, a CCR10 ligand expressed 
on keratinocytes, has been implicated in both skin and nodal 
homing of CTCL cells. Anti-CCR4 is currently being evalu-
ated in clinical trials including CTCL patients.
Naturally  occurring  regulatory T  cells  (Tregs, 
CD4+ CD25+ FOXP3+ phenotype) suppress the activity 
of other immune cells and thus maintain immunological 
tolerance. Tregs appear to be dysregulated in CTCL.36 
Early cutaneous lesions in patients with mycosis fungoides 
contain numerous FOXP3+-infiltrating Tregs that decrease 
in number in advanced lesions. The high frequency of 
FOXP3+-infiltrating Tregs may suppress tumor proliferation 
and have been correlated with improved survival.36 Patients 
with Sézary syndrome have very low levels of Tregs but 
high levels of malignant T cells expressing a Treg phenotype 
(FOXP3+ CD25-). These malignant FOXP3 + Tregs express 
CTLA-4, IL-10, and transforming growth factor-β, which 
suppress immunity and diminish the antitumor response.19
Cytotoxic T lymphocyte antigen (CTLA-4) is a 
coinhibitory molecule expressed on T cells that inhibits 
T cell activation and proliferation37 and confers resistance 
against activation-induced cell death.38 Tregs also con-
stitutively express CTLA-4, which is necessary for their 
functioning to maintain peripheral tolerance and to prevent 
autoimmunity.39,40 High CTLA-4 expression was found 
in peripheral blood mononuclear cells from patients with 
mycosis fungoides, and higher expression levels correlated 
with increased tumor burden. Th1-derived cytokines, such 
as IL-2 and IFN-γ, upregulate expression of CTLA-4.41 
Whether increased CTLA-4 expression relates to Treg-like 
properties that CTCL cells acquire during disease progression 
is not clear; further research is needed to prove this concept. 
Anti-CTLA-4 (ipilimumab) is an important immunothera-
peutic strategy in melanoma; the association of dysregulated 
CTLA-4 in CTCL suggests a potential therapeutic target in 
this disease.
Epigenetic mechanisms of pathogenesis
DNA methylation of CpG islands in promoter regions is 
an epigenetic mechanism of gene expression that tightens 
chromatin around nucleosomes and interferes with binding of 
transcription factors.42 This has been shown to downregulate 
expression of tumor suppressor genes, leading to carcinogen-
esis in several tumor types.43 In CTCL, promoter hypermethy-
lation leads to dysregulation of the cell cycle (p15, p16, p73), 
apoptosis (TMS1, p73), DNA repair (MGMT), chromosomal 
instability (CHFR), and microsatellite instability (MLH1) 
genes and proteins.44–48 Promoter hypermethylation of p15, 
p16, and MLH1 was found in both early and advanced stages 
of mycosis fungoides and Sézary syndrome, suggesting that 
early epigenetic alterations were responsible for the inactiva-
tion of these genes.46–48
When genes are hypermethylated and silenced, the his-
tones are in a deacetylated state.42 Acetylation of histones 
in nucleosomes alters conformation of chromatin. Histone 
deacetylases (HDACs) remove acetyl groups, leading to 
compaction of chromatin and repression of transcription.49 
In addition to their action on histones, HDACs also regulate 
various transcription factors, such as the p53 tumor suppres-
sor and E2F oncogene.49 HDACs were initially developed 
to restore tumor suppressor and cell regulatory genes by 
inducing histone hyperacetylation.50
Apoptotic mechanisms of pathogenesis
Defective regulation of apoptosis is a central feature of the 
pathology of several lymphoma types, including mycosis 
fungoides and Sézary syndrome. Apoptosis can be triggered 
by death receptors that belong to the tumor necrosis factor 
receptor family or by aberrations in expression of the B cell 
lymphoma-2 (Bcl-2) family. Malignant CD4+ T cells from 
cutaneous lesions and peripheral blood samples in mycosis 
fungoides and Sézary syndrome have decreased and/or defec-
tive Fas expression, and decreased Fas expression has been 
correlated with more aggressive disease as well as resistance 
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to Fas-mediated apoptosis.51–54 Thus, downregulation of 
Fas may be one way in which CTCL cells become resistant 
to chemotherapy. Downregulation of Fas in CTCL occurs 
through multiple mechanisms, ie, mutations in the Fas gene,52 
production of nonfunctioning splice variants,55 and promoter 
hypermethylation.56 In this context, malignant T cells in 
CTCL may acquire resistance to FasL signaling through 
increased expression of cFLIP, an intracellular apoptosis 
inhibitor.51
The expression of other antiapoptotic molecules, such as 
p53 and Bcl-2 family members, has been studied in CTCL. 
In one in vitro study, p53 mutations were identified in tumor 
stage mycosis fungoides, but not in patch/plaque mycosis 
fungoides.57 In another study, there was no correlation 
between clinical stage and p53 mutations.58 One pathway 
being targeted for antineoplastic therapy is the antiapoptotic 
Bcl-2 and Bcl-2-like family of proteins. T cells generally 
express Bcl-2 that inhibits apoptosis and is widely and stably 
expressed in all stages of mycosis fungoides.59 Data suggested 
that inhibition of Stat3 signaling in CTCL cells through the 
Jak kinase inhibitor, Ag490, induced apoptosis through 
decreased expression of antiapoptotic Bcl-2 and increased 
expression of the proapoptotic Bax protein.60   Surprisingly, 
other investigators found late-stage disease and shorter sur-
vival time were correlated with decreased Bcl-2 expression.58 
However, information about quantification of Bcl-2 protein 
expression was not provided. It also remains unclear whether 
the low expression is related to alterations of genes, such as 
p53, that impact Bcl-2 expression.
Polo-like kinase 1 (Plk1) is a member of the PLK family 
of serine/threonine kinases crucial to the cell division cycle, 
which has been postulated to induce oncogenesis in multiple 
solid and hematologic malignancies.61–64 Increased expres-
sion has been found with progression and metastasis. Plk1 
expression is elevated in CTCL, and in particular is found in 
tumor-stage and in folliculotropic and erythrodermic types 
of CTCL.65,66 In vitro studies with both small molecule inhi-
bition and shRNA-mediated knockdown of Plk1 resulted in 
decreased cell growth, decreased cell viability, G2/M arrest, 
and apoptosis in CTCL cells.66 In addition, CTCL cell lines 
with p5335 and k-ras36 mutations appear to be sensitive to 
Plk inhibition and may serve as biomarkers for patient 
selection. Currently there are a number of Plk inhibitors in 
preclinical development,67 and results have been reported 
from Phase I studies for four of them (BI 2536,68 GSK 
461364,69 ON-01910,70 and HMN-21471). Although these 
inhibitors were studied mainly in solid tumors, with modest 
responses reported and prolongation of stable disease at best, 
they have yet to be studied in CTCL. Plk1 could serve as a 
potential target in advanced stages, when its expression is 
generally high.
The existence of multiple mechanisms of oncogenesis 
in CTCL and the variety of mechanistic combinations in 
individual patients may perhaps require more   individualized 
therapy. A recent report of cotreatment with the HDAC 
inhibitor, panobinostat, and the Bcl-2 antagonist, ABT-737, 
found synergistic induction of apoptosis in CTCL cells.72
Molecular mechanisms of pathogenesis
Genome-wide analysis of chromosomal alterations is increas-
ingly used as a research tool in the search for novel agents 
to treat CTCL.73–75 Improvements in microarray technology 
and computational analysis of genomic data have led to dis-
coveries of underlying chromosomal mutations in tumor sup-
pressor and oncogenes involved in CTCL.73–75   Chromosomal 
regions with significant gains include 8q (including the MYC 
oncogene), 17q, and 10p13 (including GATA3, a transcrip-
tion factor which promotes Th2 cytokine production).74 
  Additionally, a recent study suggested that amplifications 
on 4q12 (including KIT), 7p11.2 (including EGFR), and 
17q25.1 may be highly associated with patients refractory 
to treatment.74 Specific oncogenes have been examined for 
defining new prognostic factors in CTCL. Deletions have 
been found on chromosomes 17p (including TP53), 10p, 
and 10q (including PTEN and FAS), 13q including RB1, and 
9p21.3 (including CDKN2A).74
MicroRNAs (miRNAs) are small noncoding RNAs that 
regulate gene expression. miRNAs have been shown to 
become dysregulated in cancer, providing the basis for devel-
opment of miRNA-targeted cancer therapies.76 A microar-
ray screen found that five miRNAs (miR-203, miR-205, 
miR-326, miR-663b, and miR-711) distinguish CTCL from 
benign skin diseases, with an accuracy of greater than 90%.77 
In tumor-stage mycosis fungoides, miR-93, miR-92A, and 
miR-155 were upregulated in comparison with benign inflam-
matory skin diseases.78 In Sézary syndrome, most miRNAs 
were downregulated, but miR-21, miR-486, and miR-214 
are upregulated and are involved in apoptotic resistance.79 
miR-21 has been shown to mediate oncogenic signaling by 
STAT3 and may be a possible therapeutic target for Sézary 
syndrome.27,80
Current and emerging therapies  
for early-stage disease
Patients with early-stage mycosis fungoides often pres-
ent with disease limited to the skin without systemic 
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  involvement; in these patients, a durable response can be 
achieved in approximately 60%–80% of cases with skin-
directed therapies. Patients with early-stage disease may 
be effectively treated with topical agents, because previous 
data have demonstrated that there is no benefit to aggres-
sive use of systemic chemotherapy.81 Existing therapeutic 
approaches include phototherapy with psoralen plus ultra-
violet A (PUVA), narrowband ultraviolet B (NB-UVB), total 
electron beam irradiation (TSEBT), and topical formulations 
of corticosteroids, nitrogen mustard, and retinoids/rexinoids. 
Success rates with PUVA are 90% for stage IA, 76% for stage 
IB, 78% for stage IIA, 59% for stage IIB%, and 61% for stage 
III CTCL.82–84 The most common reported acute side effects 
were erythema, pruritus, and nausea. Long-term exposure 
was associated with an increased risk for developing chronic 
photodamage and nonmelanoma skin cancer.84
Recent consensus from the EORTC indicates that patients 
with patches and thin plaques should be given NB-UVB 
treatment, whereas PUVA should be reserved for patients 
with folliculotropic mycosis fungoides, failure of NB-UVB 
treatment, or dark complexion, due to carcinogenic effects, 
as well as a paucity of available treatment centers.85 Early-
stage refractory patients may benefit from combination 
therapies, such as NB-UVB or PUVA with low-dose systemic 
oral bexarotene, acitretin, or IFN-α.86 High-potency topical 
corticosteroids have also been shown to have an overall 
response rate of .90% in patch-stage mycosis fungoides, 
with some side effects of irritant dermatitis and cutaneous 
atrophy.87,88 Topical nitrogen mustard has a complete response 
rate of 76%–80% for stage IA and 35%–68% complete 
response rate for stage IB disease.89 Common side effects 
are contact hypersensitivity reactions. Bexarotene gel is a 
retinoid X receptor agonist and is approved for early-stage 
mycosis fungoides.90 In clinical trials, it has been shown to 
have an overall response rate (ORR) of 54% and a complete 
response rate of 10% in patients with stages IA–IIA mycosis 
f  ungoides. It commonly causes skin irritation. Tazarotene gel, 
a retinoic acid receptor agonist, is another topical retinoid 
approved for use in psoriasis and acne, and has been shown 
to improve skin lesions in refractory mycosis fungoides and 
may be useful as an adjuvant topical treatment.91 TSEBT is 
a procedure that involves administering ionizing radiation 
to the entire skin surface.83 TSEBT has been shown to be an 
effective therapy for palliation of the cutaneous symptoms of 
mycosis fungoides and Sézary syndrome.83 Because the elec-
tron beam radiation in TSEBT has greater energy and depth 
of penetration than other skin-directed therapies, it may be an 
option for treatment of stage T2 or T3 mycosis fungoides.83 
Options may be limited for Caucasian patients, and TSEBT 
toxicity can be cosmetically disfiguring. A recent study from 
Stanford followed 180 patients with T2 or T3 mycosis fungoi-
des on TSEBT treatment and found that all patients had over 
50% improvement in skin involvement, with 63% achiev-
ing a complete clinical response (75% for T2 patients and 
47% for T3 patients) with a median duration of response of 
29 months in T2 patients and 9 months in T3 patients.83 These 
results confirm the work of previous studies showing that a 
conventional dose (30–36 Gy) of TSEBT is significantly more 
efficacious in T2 than in T3 mycosis fungoides.
Newer topical and investigational therapies include 
  Toll-like receptor (TLR) agonists, gene therapy agents, 
308 nm excimer laser, and photodynamic therapy. Imiquimod 
(Aldara® cream 5%), a TLR-7 agonist that induces tumor 
necrosis factor (TNF)-α, IFN-α, and IFN-γ expression, has 
been shown to cause clinical and histologic clearance of lim-
ited skin lesions in a small number of patients.92–95 TG-1042 
is a replication-deficient adenovirus vector expressing 
IFN-γ that has been shown to induce a Th1 response when 
injected intralesionally.96 A recent Phase II trial of repeated 
intralesional TG-1042 injections had a local response rate of 
46% in CTCL patients and minimal adverse effects, includ-
ing injection site reactions, lymphopenia, fever, and chills.97 
Further, 308 nm excimer laser has been shown to be an 
effective and well tolerated therapy for limited-stage mycosis 
fungoides in several small studies. It may be preferred over 
NB-UVB due to its greater precision in localizing treatment 
to small skin lesions, leading to decreased phototoxicity 
and better patient compliance. However, cost and avail-
ability are limitations.98–103 Photodynamic therapy utilizes a 
photosensitizer, light, and oxygen to induce reactive oxygen 
species. Two photosensitizers, 5-aminolevulinic acid (ALA; 
Levulan®) and methyl aminolevulinate hydrochloride have 
been used in CTCL. Treatment with ALA had efficacy in 
localized CTCL but not in tumor-stage CTCL, possibly due to 
insufficient penetration of 5-ALA and/or light.104,105   Common 
adverse effects of ALA include pain that occurs during light 
exposure, erythema, edema, and postinflammatory pig-
ment changes.106 Due to the limited efficacy and side effect 
profile of ALA, other photosensitizers have been recently 
tested in CTCL. Methyl aminolevulinate hydrochloride, 
the methyl ester derivative of ALA, with greater lipophilia 
resulting in increased penetration and less pain, induced a 
complete response in six of seven cases of resistant unile-
sional patch-stage mycosis fungoides, with no recurrence 
during follow-up periods from 12 to 34 months.107–109 Silicon 
phthalocyanine Pc 4 has been shown to induce apoptosis in 
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peripheral blood mononuclear cells from patients with Sézary 
syndrome.110 Hypericin ointment, another photosensitizer, 
induced a response in a Phase II trial of 12 patients, with 
adverse effects of burning, itching, erythema, and pruritus 
at the site of application.111
Current and emerging therapies  
for advanced-stage disease
Biological therapies
Patients with advanced disease (stage IIB–IVB) may have 
disseminated disease into lymph nodes and other organs, 
and may exhibit multiple immune derangements necessitat-
ing systemic therapy. While no regimen has been proven to 
prolong survival in the advanced stages, immunomodulatory 
regimens should be used initially to reduce the need for cyto-
toxic therapies. Decreased cell-mediated immunity with a 
dominant Th2 cytokine profile is observed in advanced stages 
of mycosis fungoides and Sézary syndrome. Bexarotene, 
immunomodulatory cytokines such as IFN-α, IFN-γ, and 
IL-12, and extracorporeal photopheresis enhance the host 
antitumor response by either maintaining Th1 skewing or 
inhibition of Th2 cytokine production.
Extracorporeal photopheresis, approved in 1988 by the 
US Food and Drug Administration (FDA) for the palliative 
treatment of patients with CTCL, is best suited to patients 
with Sézary syndrome, within 2 years of disease onset, near 
normal counts of CD8+ T cells and natural killer cells, and 
modest tumor burden.112 Overall response rates have ranged 
from 31% to 73% when CTCL patients are treated with 
extracorporeal photopheresis as monotherapy, but have been 
shown to have greater efficacy in various combinations with 
IFN-α, IFN-γ, granulocyte-macrophage colony-stimulating 
factor, and bexarotene, due to enhancement of antitumor 
immunity.113,114 The novel continuous flow separation system 
(Therakos™ Cellex™) has been developed based on the cur-
rent Uvar® XTS™ photopheresis device and is designed to 
reduce treatment times and extracorporeal volumes.
IFN-α is one of the most widely used first-line treatments 
and probably the most effective single agent in the treatment 
of CTCL. It has shown a wide range of biologic effects, 
including antiviral, antiproliferative, and immunomodulatory 
actions. The exact mechanism by which interferons exert their 
antitumor effects remains unknown. Th1 cytokines support 
cytotoxic T cell-mediated immunity and it has been specu-
lated that IFN-α maintains or enhances a Th1 cell population 
balance for an effective cell-mediated response to malignant 
T lymphocytes. A response rate of 73% in stage IA–IIA and 
60% response in stage IIB–IVA disease has been seen with 
IFN-α monotherapy.115 When IFN-α is used in combination 
with PUVA, both overall response rates and response dura-
tion show improvement, with studies demonstrating overall 
response and complete response rates of 98% and 84%.116,117 
While the optimal dose and duration has not been established 
yet in CTCL, current experience suggests that therapy should 
be given at a starting dose of 1–3 million units five times 
weekly, with gradual escalation to 6–9 million units daily 
or as tolerated.
Denileukin diftitox
Denileukin diftitox (Ontak®) is an IL-2 diphtheria toxin 
fusion protein targeted against malignant T cells expressing 
CD25, the high-affinity IL-2 receptor. Denileukin diftitox 
was approved by the FDA in 1999 for the treatment of 
patients with CTCL refractory to standard treatment options. 
In general, response rates in patients with relapsed and 
refractory mycosis fungoides or Sézary syndrome range 
from 30% to 37%.118 A recent randomized Phase III trial in 
CD25 + CTCL demonstrated an ORR of 44% for patients 
treated with denileukin diftitox versus 15.9% for patients 
on placebo. CTCL patients were randomly assigned to 
denileukin diftitox 9 µg/kg/day (n = 45), denileukin   diftitox 
18 µg/kg/day (n = 55), or placebo infusions (n = 44). In 
addition, patients treated with both doses of denileukin 
diftitox had a significantly longer progression-free survival 
than patients on placebo.119 The incidence of grade 3 and 4 
capillary leak syndrome was seen in 2–3 patients (3.6%) at 
doses of 18 µg/kg/day. A key remaining question of whether 
response to denileukin diftitox depends on expression of 
CD25 was explored in a retrospective study of complete 
responders in previous Phase II and Phase III trials. This 
study found no difference in response between patients with 
CD25-positive and CD25-negative disease.120
Histone deacetylase inhibitors
HDAC inhibitors were initially developed to modulate 
chromatin condensation by acetylation of histones affect-
ing gene expression. More recently, their effects on post-
translational modification of many intracellular proteins have 
been recognized.121 Vorinostat (suberoylanilide hydroxamic 
acid; Zolinza®), an orally administered HADC inhibitor, 
was approved by the FDA in 2006 for the treatment of 
relapsed/refractory CTCL. A Phase IIB trial was conducted 
in 74 patients with stage IB–IVA CTCL, including 82% 
with $stage IIB disease. ORR was 29.7%. Oral vorinostat 
was administered at 400 mg daily. The median time to 
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response was 2 months and median duration of response was 
not reached, but was estimated to be longer than 6.1 months. 
In addition, 43.4% of patients with severe pruritus experi-
enced relief. The most common adverse effects included 
diarrhea, fatigue, and nausea, but most were of grade 2 or 
lower. Significant grade 3 side effects included pulmonary 
embolism (5%) and thrombocytopenia (5%). In this study, 
QTc interval prolongation was observed in three patients with 
no reported clinical sequelae, none of which were grade 3. 
There were no cases of infection.122 Another Phase II trial of 
vorinostat conducted in 33 patients with advanced or refrac-
tory CTCL at multiple doses demonstrated an ORR of 24% 
with a median time to response of 3 months and a median 
duration of response of 3.7 months. Forty-five percent of 
patients experienced relief of pruritus.123 In addition, analysis 
of lesion biopsies in responding patients demonstrated a shift 
in localization of phosphorylated STAT-3 from nuclear to 
cytoplasmic, suggesting that vorinostat may inhibit prolif-
eration of CTCL cells by inactivating STAT3.124 Further in 
vitro work has shown that CTCL patients with high nuclear 
levels of STAT1 and pSTAT3 are resistant to vorinostat.124 
Combination therapy has also been investigated, and PI3 K 
inhibitors have been found to synergize with vorinostat in 
reducing cell viability.125
Romidepsin (depsipeptide, Istodax®) is another HDAC 
inhibitor recently approved by the FDA for patients with 
relapsed/refractory CTCL. Two Phase II trials were con-
ducted in a total of 167 patients suffering from relapsed, 
refractory, or advanced CTCL.126,127 Romidepsin was 
administered intravenously at 14 mg/m2 on days 1, 8, and 
15 of a 28-day cycle. In both trials, the ORR was 34%, the 
complete response rate was 6%, the median time to response 
was 2 months, and median duration of response was longer 
than 12 months. The most common adverse effects were 
fatigue, nausea, vomiting, and anorexia. Severe adverse 
effects included leukopenia, lymphopenia, granulocytopenia, 
thrombocytopenia, and anemia. Earlier studies have shown 
that HDAC inhibitors may be associated with electrocardio-
graphic abnormalities, such as QTc interval prolongation.128 
In one trial, 9% of patients had QTc prolongation and 
80% had asymptomatic T wave flattening or ST segment 
  depression.126 The other trial had no patients with QTcF 
values .480 milliseconds or an increase of .60 milliseconds 
over baseline. It was also found that antiemetics might contrib-
ute to QTcF prolongation.127
Panobinostat (LBH589) is another HDAC inhibitor that 
was shown in a Phase I trial to induce clinical responses 
in CTCL patients.129 Preliminary results of a Phase II trial 
of oral panobinostat have been reported. Panobinostat was 
administered at a dose of 20 mg on days 1, 3, and 5 weekly 
in bexarotene-treated patients and bexarotene-naïve patients. 
In 62 bexarotene-treated patients, 17.7% achieved a response. 
In 35 bexarotene-naïve patients, 12.1% achieved a response. 
Thrombocytopenia, neutropenia, pruritus, diarrhea, and hypo-
phosphatemia were the most common grade 3 or 4 toxicities. 
Two patients had QTcF . 480 milliseconds and four had an 
increase in QTcF . 60 milliseconds from baseline.130
Another HDAC inhibitor, belinostat (PDX101), is 
currently being evaluated in a Phase II trial of patients 
with relapsed/refractory peripheral T cell lymphoma that 
includes anaplastic large cell lymphoma and subcutaneous 
panniculitis-like T cell lymphoma. The treatment schedule 
is 1000 mg/m2 intravenously on days 1–5 of a 21-day cycle. 
Of 19 evaluable patients so far, the ORR was 32% with a 
median time to response of 8 months.
Monoclonal antibodies
Monoclonal antibodies target tumor cells via cell surface 
markers upregulated on malignant T cells such as CD4, 
CD52, and CCR4. Zanolimumab (Hu-Max CD4) is a human-
ized anti-CD4 monoclonal antibody that has been shown in 
vitro to mediate antibody-dependent cellular cytotoxicity, 
primarily in CD4 + CD45RO + T cells.131 Zanolimumab also 
blocks T cell activation by macrophages in Pautrier’s micro 
abscesses via induction of inhibitory signaling pathways 
involving SHIP-1 and DOK-1.132 In two Phase II studies 
done in 47 patients with refractory early-stage and advanced-
stage CTCL, zanolimumab was given intravenously at a 
weekly dose of 280 mg and 560 mg for early-stage patients 
and 280 mg and 980 mg for late-stage patients. The ORR 
was 56% in patients with mycosis fungoides treated with a 
high dose and 15% at a lower dose. In patients with Sézary 
syndrome, the ORR was 20% in patients treated with a high 
dose and 25% at a lower dose. Adverse events included skin 
inflammation (24%) and infections of the skin and upper 
respiratory tract (49%).133
Alemtuzumab (Campath®), a humanized monoclonal 
antibody against CD52 surface antigen expressed on most 
malignant T cells, has been shown to mediate antibody-
dependent cellular cytotoxicity,134,135 complement-mediated 
cell lysis,136 and apoptosis.137 A Phase II study was conducted 
in 22 patients with advanced CTCL at a dose of 30 mg 
intravenously three times a week. The ORR was 55% (32% 
complete response, 23% partial response). A greater effect 
was observed in patients with erythrodermic CTCL (69% 
ORR) than on plaque or tumor CTCL (40%).138 To   investigate 
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this preferential effect on erythrodermic CTCL, another 
Phase II study was conducted in 19 patients with advanced 
refractory erythrodermic CTCL and found an ORR of 84%.139 
Serious adverse events in these studies included infections 
and hematologic toxicity. Infections, occurring primarily in 
patients who had received three or more treatments, included 
cytomegalovirus reactivation, fever of unknown origin, 
herpes simplex virus reactivation, pulmonary aspergillosis, 
and Mycobacterium pneumonia. Hematologic toxicities 
included anemia, neutropenia, and thrombocytopenia. One 
study found adverse effects of congestive heart   failure and 
arrhythmias following alemtuzumab treatment.140   However, 
several studies since have found no correlation with 
cardiac toxicity.139,141
Chemotherapy
Conventional systemic treatments include chemothera-
peutic agents and biologic immunomodulatory therapies. 
  Gemcitabine (Gemzar®) and pegylated doxorubicin (Doxil®) 
are being used as newer initial single-agent chemotherapeu-
tic choices.142,143 A Phase II trial of gemcitabine reported a 
68% ORR in 25 patients with refractory advanced CTCL.144 
In advanced untreated CTCL, gemcitabine was shown to 
result in a 75% response rate in 32 patients.142 Another study 
showed a response rate of 88% for pegylated liposomal 
doxorubicin.143
Pralatrexate: targeted antifolate therapy
Methotrexate is the traditional antifolate used in therapy for 
lymphomas. It inhibits dihydrofolate reductase that converts 
dihydrofolate to tetrahydrofolate, which is required for 
synthesis of thymidylate and purine nucleotides involved in 
DNA and RNA synthesis. Pralatrexate (Folotyn®) belongs to 
a class of novel folate analogs, ie, the 10-deazaaminopterins, 
designed with greater affinity than methotrexate for receptor-
reduced folate carrier, leading to improved drug internaliza-
tion through membrane transport. It is also a better substrate 
for polyglutamylation than methotrexate, leading to greater 
intracellular retention145,146 and 10-fold greater cytotoxicity 
than methotrexate in lymphoma cell lines.147 Pralatrexate 
has been approved by the FDA for relapsed or refractory 
peripheral T cell lymphoma.
Preliminary results of a multicenter dose-escalation 
Phase II study in 54 patients with relapsed or refractory 
CTCL have been reported. The starting dose and schedule 
was 30 mg/m2 intravenously once per week for 3 of 4 weeks. 
An optimal dose of 15 mg/m2 for 3 of 4 weeks was defined, 
at which the ORR was 43%. The ORR was 50% at doses 
greater than 15 mg/m2. Most common grade 1–2 adverse 
effects included fatigue, mucositis, nausea, edema, epistaxis, 
pyrexia, constipation, and vomiting. Grade 3 adverse effects 
included thrombocytopenia, neutropenia, leukopenia, and 
anemia.148 In another report of 12 patients with mycosis 
fungoides and large-cell transformation who were part of 
the multicenter PROPEL (Pralatrexate in Patients With 
Relapsed or Refractory Peripheral T-Cell Lymphoma) trial 
for patients with peripheral T cell lymphoma, the ORR was 
58% via investigator assessment and 25% via independent 
central review.149,150 Combination therapy with bortezomib 
is currently under exploration.151
Hematopoietic stem cell transplantation
The concept of high-dose combined chemotherapy followed 
by autologous bone marrow transplant or peripheral blood 
stem cell support has curative potential in various non-
Hodgkin lymphomas, but experience in CTCL is limited. 
Autologous stem cell transplants have yielded disappointing 
results. Despite reported effective responses with complete 
response in most patients treated, relapses are frequent and 
may occur rapidly.152,153 Allogeneic hematopoietic stem cell 
transplantation (HSCT) with myeloablative conditioning 
regimens provides a graft-versus-tumor effect and avoids 
reinfusion of tumor cells, both of which are features lack-
ing in autologous HSCT. However, myeloablation places 
the patient at high risk for infections and graft-versus-host 
disease, rendering HSCT difficult to use in the elderly and in 
those with multiple comorbidities. With the broadened use of 
nonmyeloablative reduced-intensity conditioning regimens, 
allogeneic HSCT may now be better suited for patients with 
CTCL.154 A retrospective study of 60 patients with advanced 
CTCL who received allogeneic HSCT and either reduced-
intensity conditioning or myeloablative conditioning had 
a complete response rate of 60.5% and an overall survival 
of 54% at 3 years. Overall survival at 3 years in patients 
who received reduced-intensity conditioning was 63% 
compared with 29% in patients who received myeloablative 
  conditioning. The median age of the patients was 46.5 years, 
indicating that allogeneic HSCT may be an effective treatment 
in younger as well as older patients.155 In another study of 
allogeneic HSCT with reduced-intensity conditioning and pre-
treatment TSEBT for tumor debulking, 58% had a complete 
response, and overall survival at 2 years was 79%. Causes 
of mortality included sepsis, metastatic nonsmall cell lung 
cancer, and disease progression.156 Cord blood transplantation 
has also been attempted with some success in Japan in cases 
of failure or inability to attempt allogeneic HSCT.157,158
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
83
CTCL and new targets for therapyCancer Management and Research 2012:4
Investigational therapies
Lenalidomide
Lenalidomide (Revlimid®), an analog of thalidomide, is cur-
rently approved by the FDA for treatment of myelodysplastic 
syndrome159 and refractory/relapsed multiple myeloma.160 
Its immunomodulatory properties, such as natural killer and 
T cell activation with induction of Th1 cytokine production 
and cytotoxic activity, along with alteration of the tumor cell 
microenvironment through antiangiogenic, antiproliferative, 
and proapoptotic properties, provided the rationale to use this 
agent in patients with CTCL.161 A Phase II trial in 35 patients 
with advanced/refractory CTCL showed an ORR of 32%, a 
median time to response of 3 months, and a median duration 
of response of 4 months.162 The most common side effects 
were fatigue, lower leg edema, gastrointestinal symptoms, 
leukopenia, and neutropenia. Temporary tumor flares, charac-
terized by an increase in size/number of skin lesions, tender 
swelling of lymph nodes, or increase in Sézary cell count, 
were noted in 25% of patients following initial treatment. 
Data from this study also suggest that the immunomodulatory 
effects of lenalidomide might be associated with decreased 
Treg and CD4+ T cell numbers.
Oligonucleotides (nuclear acid  
therapeutics)
TLR agonists represent a novel approach to stimulate an 
effective antitumor immune response in patients with CTCL 
through augmentation of either dendritic cells or T cell 
effects. PF-3512676 (CPG-7909, ProMune®) is a TLR-9-
activating oligodeoxynucleotide and potent plasmacytoid 
dendritic cell stimulator163 that was recently shown in a 
dose-escalating Phase I trial to induce an ORR in 32% of 
patients (three complete responses, six partial responses) with 
treatment-refractory stage IB to IVA CTCL.164 Twenty-eight 
patients received subcutaneous doses (0.08, 0.16, 0.24, 0.28, 
0.32, or 0.36 mg/kg) once weekly for 24 weeks.
Proteasome inhibitors
Nuclear factor-kappa B (NF-kB) is an oncogenic transcrip-
tion factor normally sequestered in an inactive state by the 
inhibitory I-kB molecule. Various oncogenic signals activate 
NF-kB via phosphorylation of I-kB, leading to its degrada-
tion via the 26S proteasome. Downstream targets of NF-kB 
include cIAP1, cIAP2, and Bcl-2.165 Bortezomib inhibits the 
26S proteasome and therefore prevents degradation of I-kB 
and activation of NF-kB.166 It has been shown to induce apop-
tosis in CTCL via suppression of NF-kB-dependent antiapop-
totic genes, cIAP1 and cIAP2, but not Bcl-2.165,167 A Phase II 
trial was conducted in 15 patients with relapsed/refractory 
cutaneous T cell lymphoma using a dose of 1.3 mg/m2 on 
days 1, 4, 8, and 11 every 21 days, for a total of six cycles. 
The ORR was 67% (17% complete responses, 50% partial 
responses). Common adverse effects were neutropenia, 
thrombocytopenia, and sensory neuropathy.168 Currently, 
a Phase I trial is being conducted in patients with refractory 
T cell lymphoma using a combination of bortezomib and 
5-azacytidine, a DNA methyltransferase inhibitor.
CCR4 antibody
KW-0761, a novel defucosylated humanized monoclonal anti-
body against CCR4, enhances antibody-dependent cellular 
cytotoxicity against malignant CTCL cells.169 In vitro studies 
of KW-0761 using mycosis fungoides and Sézary syndrome 
cell lines, primary mycosis fungoides and Sézary syndrome 
cells, and mycosis fungoides and Sézary syndrome mouse 
models showed not only significant antibody-dependent 
cellular cytotoxicity-mediated antitumor activity, but also a 
synergistic effect with IL-12, IFN-α-2b, and IFN-γ. Phase I 
studies in adult T cell leukemia/lymphoma and peripheral 
T cell lymphoma have demonstrated an ORR of 31%, with 
minimal adverse effects, consisting mainly of hematologic 
toxicities.170 Phase II studies are currently ongoing in patients 
with peripheral T cell lymphoma, CTCL, and adult T cell 
leukemia/lymphoma.
Conclusion
The significant strides that have been made in elucidating the 
mechanisms of pathogenesis in CTCL have allowed for the 
development of an extensive repertoire of targeted therapies. 
Patients with early-stage disease generally have an excellent 
prognosis and should be treated with skin-directed therapies. 
While no regimen has been proven to prolong survival in the 
advanced stages, immunomodulatory regimens are recom-
mended initially to reduce the need for cytotoxic therapies. 
The existence of multiple mechanisms of oncogenesis in 
CTCL allows for a variety of mechanistic combinations and 
more individualized therapy. In more advanced stages of 
CTCL, treatment efforts should be made for palliation and 
improvement of quality of life. Unfortunately, other than 
allogeneic hematopoietic stem cell transplantation, there are 
no curative therapies for CTCL.
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